Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs Measured

FuturHealth
Graded #215

Lower grade

vs+9.5
Measured
Graded #58

Higher grade

The verdict

Measured takes it — 75.1/100 to 65.6/100.

Measured grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Measured is a metabolic-health membership pairing GLP-1 treatment with 1:1 nutrition support and board-certified provider care.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMeasured +26
60
86
Dose & formulationFuturHealth +4
81
77
Clinical oversightMeasured +20
67
87
Labs & monitoringMeasured +2
61
63
FulfillmentMeasured +5
62
67
Contract termsFuturHealth +14
55
41
FuturHealth · left barMeasured · right bar

The numbers

MetricFuturHealthMeasured
WeighScore65.6/10075.1/100
GradeCC
Scorecard rank#215#58
Semaglutide$199/mo (compounded)$119/mo (compounded)
TirzepatideNot disclosed$219/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesInjection only
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Measured

Graded #58 · C

Strengths

  • Membership includes 1:1 nutrition support and board-certified provider care
  • Both compounded (from $79/mo microdose, $119 semaglutide, $229 tirzepatide) and brand-name Wegovy/Zepbound
  • Insurance or cash-pay options for brand-name medications
  • Oral option available (Wegovy pill); cancel-anytime membership

Where it loses points

  • The headline $79 'GLP-1 Microdose' is a promotional rate off a $99 list price, is filed by the provider under longevity rather than weight loss, and is not a labelled therapeutic dose of either molecule
  • Branded plans are a $49/mo membership with the medication billed separately at $149 to $449/mo
  • The site never states which billing term its 'from' prices assume, though the terms allow monthly, quarterly, semi-annual and annual
  • No state count is published
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard